Clinical trial NCT06349096: Safety And Efficacy Investigation Of The Effects Of ClearLift Q-Switched Nd:Yag 1064nm Laser Module In The Treatment Of Facial Skin Wrinkles
Official title: Open-Label, Safety And Efficacy Investigation Of The Effects Of ClearLift Q-Switched Nd:Yag 1064nm Laser Module In The Treatment Of Facial Skin Wrinkles
Study type: INTERVENTIONAL
Overall status: NOT_YET_RECRUITING
Phase: NA
Conditions: Facial Skin Wrinkles
Lead sponsor: Alma Lasers
Sponsor class: INDUSTRY
First posted: 2024-04-05
Enrollment: 36
Sex: FEMALE
Minimum age (years): 35
Maximum age (years): 55
Standard ages: ADULT
Accepts healthy volunteers: yes
Allocation: NA
Intervention model: SINGLE_GROUP
Primary purpose: TREATMENT

Brief summary: Alma Lasers ClearLift is a fractional non-ablative Q-Switched laser, allowing practitioners to use the benefits of a high intensity QS laser for the treatment of aged skin. Alma Harmony ClearLift uses a fractional QS laser to achieve a deep mechanical effect beneath the epidermis via a photoacustic effect. This creates a controlled dermal wound while leaving the epidermis intact. The wound healing process stimulates growth of new collagen, skin contracture and tightening. This procedure is virtually painless with no downtime and is safe for all skin types.

Based on this background, we have considered an interest to design a study aimed at assessing the efficacy and safety of a treatment course with ClearLift Module in patients with facial skin wrinkles


Eligibility criteria: Inclusion Criteria:

* Female subjects aged ≥ 35 and ≤ 55 years
* Presence of type 1-3 facial skin wrinkles, according to the Glogau scale;
* Subjects in reasonably good general health, according to Investigator's judgment;
* Subjects who agree to avoid tanning during the entire investigational period;
* Subjects who agree to avoid any other facial procedure during the entire investigational period; including but not limited to: injectables or threads, peeling of any kind, dermabrasion, facial hair removal or application of any cosmoceutical/pharmaceutical without the consent from the PI only.
* Subjects able to understand the full nature and the purpose of the investigation, including possible risks and side effects, able to cooperate with the Investigator and to comply with the requirements of the entire investigation (ability to attend all the planned investigation visits according to the time limits included) based on Investigator's judgement.
* Subjects willing to sign an informed consent, consent to use their photos for future scientific or marketing purposes, according to the sponsor's needs.

Exclusion Criteria:

* Subjects with active infections;
* Subjects with history of keloid scarring or hypertrophic scar formation;
* Subjects with previous medical treatment of the area, or oral retinoid drug prescribed within the past six months;
* Subjects who have been tanning within the past 30 days;
* Previous surgical treatment of the area selected for the treatment with the investigational device;
* Subjects with any inflammatory skin condition e.g., eczema, active herpes simplex, etc. at the treatment site;
* Subjects with presence of tattoos at the treatment site;
* Subjects with skin cancer or any other cancer and/or any cancer drug therapy (such as ducabaxine, fluorouracil, methotrexate, etc.);
* Subjects with history of autoimmune disorder or evidence of immunosuppression;
* Subjects with cellulitis;
* Subjects with collagen vascular diseases;
* Subjects with thrombocytopenia;
* Subjects with peripheral vascular disease;
* Subjects with Melasma;
* Pregnant or lactating subjects.

Primary outcomes:
measure: Primary endpoint
timeFrame: at the 3-month follow-up
Secondary outcomes:
measure: Secondary endpoint
timeFrame: at the 1-month follow-up
measure: Secondary endpoint
timeFrame: at the 1 and 3-month follow-up
measure: Secondary endpoint
timeFrame: at the 1 and 3-month follow-up
Other outcomes:
measure: Safety & Tolerability
timeFrame: throughout the study
measure: Safety & Tolerability
timeFrame: immediately after each treatment session (up to 1 month)
Locations:
city: Tirana
country: Albania
facility: San Luca Medical Clinic
Study officials:
affiliation: Head of San Luca Medical Clinic, Tirana, Albania
name: Arminda Avdulaj, MD
role: PRINCIPAL_INVESTIGATOR
References: